Samsung Bio eyes construction of sixth manufacturing plant to kickstart 2025

Following a blockbuster 2024, Samsung Biologics is considering building a sixth manufacturing facility to meet the rising demand for biologics as it gears up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA adcomm to review Novartis’ Fabhalta in ultra-rare kidney disease

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 3, 2025

Emergency Liver Transplant Effective for Severe Acute-on-Chronic Liver Failure

BOSTON — Prioritizing emergency liver transplantation for patients with severe acute-on-chronic liver failure (ACLF) resulted in relatively good survival outcomes, according to a U.K. study

November 15, 2023

Roche’s Vabysmo reports positive outcomes in multiple eye diseases – Pharmaceutical Technology

Vabysmo is a bispecific antibody approved in multiple regions, including Europe, the UK, and the US, for the treatment of wAMD and DME. Credit: Pixel-Shot

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.